HLS Therapeutics Announces Q3 2024 Financial Results Canada NewsWire TORONTO, Nov. 7, 2024 TORONTO, Nov. 7, 2024 /CNW/ - HLS Therapeutics Inc...
HLS Therapeutics to Host Q3 Fiscal 2024 Financial Results Conference Call Canada NewsWire TORONTO, Oct. 24, 2024 TORONTO, Oct. 24, 2024 /CNW/...
HLS Therapeutics to Present at H.C. Wainwright's 26th Annual Global Investment Conference Canada NewsWire TORONTO, Aug. 28, 2024 TORONTO...
HLS Therapeutics Announces Q2 2024 Financial Results Canada NewsWire TORONTO, Aug. 8, 2024 TORONTO, Aug. 8, 2024 /CNW/ - HLS Therapeutics Inc...
HLS Announces Reimbursement for Vascepa® under Alberta's Provincial Drug Plan Canada NewsWire TORONTO, July 29, 2024 With the addition...
HLS Therapeutics to Host Q2 Fiscal 2024 Financial Results Conference Call Canada NewsWire TORONTO, July 25, 2024 TORONTO, July 25, 2024 /CNW/...
HLS Therapeutics Announces the Sale of its XENPOZYME® Royalty Interest to DRI Healthcare Trust Canada NewsWire TORONTO, July 2, 2024 Total...
HLS Therapeutics Reports Annual Meeting Results Canada NewsWire TORONTO, June 7, 2024 TORONTO, June 7, 2024 /CNW/ - HLS Therapeutics Inc...
Publication d'une nouvelle étude sur l'impact des programmes de soutien aux patients sur la persistance au traitement à la...
HLS Therapeutics Announces Q1 2024 Financial Results Canada NewsWire TORONTO, May 9, 2024 TORONTO, May 9, 2024 /CNW/ - HLS Therapeutics Inc...
HLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference Call Canada NewsWire TORONTO, April 25, 2024 TORONTO, April 25, 2024 /CNW/...
HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference Canada NewsWire TORONTO, April 9, 2024 TORONTO...
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups Canada...
HLS Therapeutics Announces Fiscal 2023 Financial Results Canada NewsWire TORONTO, March 14, 2024 TORONTO, March 14, 2024 /CNW/ - HLS Therapeutics...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads